Clinical Research Directory
Browse clinical research sites, groups, and studies.
Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty
Sponsor: Emory University
Summary
This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.
Key Details
Gender
All
Age Range
18 Years - 95 Years
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2026-07
Completion Date
2028-08
Last Updated
2026-06-03
Healthy Volunteers
No
Conditions
Interventions
Suzetrigine
Suzetrigine is an orally administered, selective NaV1.8 voltage-gated sodium channel inhibitor being investigated as a non-opioid analgesic for the treatment of pain through inhibition of pain signal transmission in peripheral sensory neurons.
Locations (3)
Emory Clinic
Atlanta, Georgia, United States
Emory Clinic at Executive Park
Atlanta, Georgia, United States
Emory Orthopaedics and Spine Center
Atlanta, Georgia, United States